Integra LifeSciences Holdings Corporation (IART) — Analyst outlook / Analyst consensus target is. Based on 26 analyst ratings, the consensus is bullish — 12 Buy, 9 Hold, 5 Sell.
The consensus price target is $15.00, representing an upside of 35.6% from the current price $11.06.
Analysts estimate Earnings Per Share (EPS) of $2.45 and revenue of $1.61B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.09 vs est $2.45 (missed -103.7%). 2025: actual $-6.73 vs est $2.20 (missed -405.7%). Analyst accuracy: 0%.
IART Stock — 12-Month Price Forecast
$15.00
▲ +35.62% Upside
Average Price Target
Based on 26 Wall Street analysts offering 12-month price targets for Integra LifeSciences Holdings Corporation, the price target is $15.00.
The average price target represents a +35.62% change from the last price of $11.06.
IART Analyst Ratings
Buy
Based on 26 analysts giving stock ratings to Integra LifeSciences Holdings Corporation in the past 3 months
EPS Estimates — IART
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.09
vs Est $2.45
▼ 2,823.9% off
2025
Actual –$6.73
vs Est $2.20
▼ 132.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect the company to turn profitable.
Revenue Estimates — IART
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.611B
vs Est $1.613B
▼ 0.2% off
2025
Actual $1.635B
vs Est $1.630B
▲ 0.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
